Encompass Health Q2 2025 Results: Net Revenue Rises 12%, EPS Up by 26.1%

Reuters
08/05
Encompass Health <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Net Revenue Rises 12%, EPS Up by 26.1%

Encompass Health Corporation, the largest owner and operator of inpatient rehabilitation hospitals in the United States, has reported its financial results for the second quarter of 2025. The company achieved a net operating revenue of $1.4577 billion, marking a 12.0% increase from $1.3012 billion in the same period of the previous year. This growth was driven by an increase in discharges and pricing, with total discharges rising by 7.2% and net patient revenue per discharge increasing by 4.2%. Income from continuing operations attributable to Encompass Health per diluted share rose to $1.40, up from $1.13, representing a 23.9% increase. Adjusted earnings per share also climbed by 26.1%, reaching $1.40 from $1.11. Additionally, cash flows provided by operating activities increased to $270.2 million, a 24.3% rise from $217.4 million in Q2 2024. Encompass Health has also updated its full-year 2025 guidance. The company now expects net operating revenue to range between $5.880 billion and $5.980 billion, revised from the previous guidance of $5.850 billion to $5.925 billion. Adjusted EBITDA is projected to be between $1.220 billion and $1.250 billion, and adjusted earnings per share from continuing operations are anticipated to be between $5.12 and $5.34.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Encompass Health Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CL43704) on August 04, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10